612 related articles for article (PubMed ID: 27576310)
1. Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
Bilek LD; Waltman NL; Lappe JM; Kupzyk KA; Mack LR; Cullen DM; Berg K; Langel M; Meisinger M; Portelli-Trinidad A; Lang M
BMC Womens Health; 2016 Aug; 16(1):59. PubMed ID: 27576310
[TBL] [Abstract][Full Text] [Related]
2. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Waltman N; Kupzyk KA; Flores LE; Mack LR; Lappe JM; Bilek LD
Osteoporos Int; 2022 Feb; 33(2):475-486. PubMed ID: 34519832
[TBL] [Abstract][Full Text] [Related]
3. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
[TBL] [Abstract][Full Text] [Related]
4. Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial.
Blay R; Flores LE; Kupzyk K; Waltman N; Lappe J; Mack L; Bilek L
Osteoporos Int; 2024 May; 35(5):877-891. PubMed ID: 38368307
[TBL] [Abstract][Full Text] [Related]
5. The influence of antiresorptive bone medication on the effect of high-intensity resistance and impact training on osteoporotic fracture risk in postmenopausal women with low bone mass: protocol for the MEDEX-OP randomised controlled trial.
Fischbacher M; Weeks BK; Beck BR
BMJ Open; 2019 Sep; 9(9):e029895. PubMed ID: 31492784
[TBL] [Abstract][Full Text] [Related]
6. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
7. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Mawatari T; Muraoka R; Iwamoto Y
Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
10. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
11. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.
Mendonça LT; Pinheiro MM; Szejnfeld VL; Castro CH
J Clin Densitom; 2017; 20(1):44-49. PubMed ID: 27616291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
14. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Ringe JD; Faber H; Farahmand P; Dorst A
Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
18. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
19. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
